MedTrace Logo

Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test

NCT06943768 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 9654

Last updated 2025-06-24

No results posted yet for this study

Summary

This is a multicenter, cross-sectional study. It is based on fecal methylation site detection, H. pylori susceptibility testing of fecal samples, and a combination of the two, compared with the "gold standard" imaging tests, CT, gastroscopy and/or pathology, for gastric cancer, benign diseases such as gastritis, and health check-ups.

Conditions

  • Gastric (Stomach) Cancer

Interventions

DIAGNOSTIC_TEST

fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing

To establish an early diagnostic test system for gastric cancer based on the methylation site detection technology in feces, with or without the combination of Helicobacter pylori gastric cancer susceptibility gene detection, and then to evaluate the clinical diagnostic value of this test system.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-04-30
Completion
2026-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06943768 on ClinicalTrials.gov